A Nutritional Supplement with a High Blend Ratio of ω-3 Fatty Acids(Prosure®) Reduces Severe Oral Mucositis and Body Weight Loss for Head and Neck Cancer Patients Treated with Chemoradiotherapy

Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and...

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 46; no. 4; p. 685
Main Authors:	Mizumachi, Takatsugu, Kano, Satoshi, Homma, Akihiro, Akazawa, Mikiko, Hasegawa, Chiharu, Shiroishi, Yoko, Okamoto, Chiaki, Kumagai, Satomi, Nishimura, Masaharu, Takasaki, Hiroyo, Takeda, Hiroshi, Yasuda, Koichi, Minatogawa, Hideki, Dekura, Yasuhiro, Onimaru, Rikiya, Shirato, Hiroki, Fukuda, Satoshi
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-04-2019
Subjects:	Chemoradiotherapy Fatty Acids, Omega-3 - therapeutic use Head and Neck Neoplasms - therapy Humans Mucositis - drug therapy Mucositis - etiology Stomatitis - drug therapy Stomatitis - etiology Weight Loss
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and the completion rate of chemoradiotherapy in patients with oropharyngeal and hypopharyngeal cancer. The study group comprised patients with oropharyngeal and hypopharyngeal cancer who were treated with concomitant cisplatin and 70 Gy of radiotherapy. These patients received 2 packs of Prosure®per day during chemoradiotherapy. A total of 17 patients were included in this study. The reduction in body weight was significantly improved compared with that in the historical control group that did not receive Prosure®(7.3% vs 10.3%, p<0.01), and the rate of Grade 3-4 oral mucositis was significantly reduced for the patient groups that received Prosure®(CTCAE v3.0 GradeB3; 24% vs 58%, p<0.05). The completion rate of chemoradiotherapy was not significantly different between both groups(77% vs 60%, NS). A nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)had effects on oral mucositis and body weight loss in head and neck cancer patients treated with chemoradiotherapy.
ISSN:	0385-0684